FDA Approval for Newly Diagnosed Acute Myeloid Leukemia
May 27, 2022•10 min•Ep. 144
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
This week, we're covering the FDA approval of a doublet therapy in certain populations of patients with newly diagnosed acute myeloid leukemia. Then we'll hear about a comparison study of treatments for patients with metastatic breast cancer and brain metastases.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Ivosidenib/Azacitidine for Certain Patients With Newly Diagnosed AML
To listen to more podcasts from ASCO, visit asco.org/podcasts.
For the best experience, listen in Metacast app for iOS or Android